

Life Science in Medicon Valley

- global outlook with regional impact

medicon valley alliance

Creating Opportunities

Welcome

On behalf of the Medicon Valley Alliance Board of Directors and the Medicon Valley Alliance team, we warmly welcome you to the Medicon Valley Alliance Annual Meeting 2020 titled “Life Science in Medicon Valley – global outlook with regional impact”.

2020 has been a challenge for all of us. The pandemic has placed our healthcare systems under enormous strain, while life science companies have worked hard to do their part in addressing the disease. Tackling COVID-19 requires coordinated, collaborative and collective efforts, and solving problems during a crisis demands speeding up innovation.

By bringing together key industry leaders, researchers and political decision-makers at this year's annual meeting, we hope to stimulate a dialogue on how we can work together across borders in Medicon Valley to build a stronger future.

Medicon Valley Alliance's vision is to position Medicon Valley as "the most competitive and vital life science cluster in northern Europe", which can function as a Nordic center of gravity for life science excellence. Our objective is to pave the way for coordinated regional, national and Nordic life science strategies, actively pursued by dedicated industry, academia and political stakeholders, that result in innovation, growth and better care for patients. We strongly believe that Medicon Valley is a key component in any such strategy.

As demonstrated by today's presentations from several MVA members who are involved in COVID-19 related research, there is an opportunity in every crisis. Hopefully, this afternoon will give us good reason for optimism, not only when it comes to the nature of the specific research areas, but also when it comes to the prospects for realizing MVA's ambitious and overall vision.

We would like to wish you a warm welcome once again, and we hope that you enjoy the conference.



Søren Bregenholt
Chairman of the board
Medicon Valley Alliance

CEO, Macrophage Pharma



Petter Hartman
CEO
Medicon Valley Alliance

Program

12:00 – 12:30 Registration, networking and sandwiches

12:30 – 12:35 Welcome

Petter Hartman, CEO, Medicon Valley Alliance

12:35 – 12:50 State of Medicon Valley – Life Science in Greater Copenhagen

Petter Hartman, CEO, Medicon Valley Alliance

12:50 – 14:00 Framework conditions for life science and innovation

12:50 – 13:15 Mobilizing the Öresund Region for Innovation: The Case of Life Sciences

Christian Ketels, Global expert on economic competitiveness and clusters

13:15 – 13:30 The need to change the healthcare system for the benefit of patients and society:

Merck's perspective

Enrique Álvarez Fernández, Managing Director and General Manager, Merck Group

13:30 – 13:45 Digital transformation for commercial life science – what are the learnings for a post COVID-19 world?

Berkeley Vincent, Managing Director Nordic Cluster, Janssen Europe, Middle East & Africa

13:45 – 14:15 Coffee break & networking

14:15 – 15:20 Investment focus

14:15 – 14:30 Funding opportunities for innovation in life science: New partnerships in the eco system

Anne-Marie Levy Rasmussen, CEO, Innovation Fund Denmark

- 14:30 – 14:45 We need system innovation in life science and society as a whole. But how?
Darja Isaksson, Director General, Vinnova
- 14:45 – 15:00 Eir Ventures: Regional investment with an international perspective
Amanda Hayward, Partner, Eir Ventures
- 15:00 – 15:20 Lounge discussion
- 15:20 – 15:50 Coffee break & networking**
- 15:50– 17:00 Innovation during COVID-19**
- 15:50 – 16:05 Necessity is the mother of invention – how an unprecedented global need facilitated new constellations within biotech
Martina Kvist Reimer, Executive Vice President, Red Glead Discovery
- 16:05 – 16:20 A versatile vaccine platform – antigen display on the surface of the capsid like particles
Morten Agertoug Nielsen, Associate Professor, CMP, Dept. of Immunology and Microbiology, University of Copenhagen
- 16:20 – 16:35 The potential of stem cells in treating COVID-19 ARDS
Evy Lundgren-Åkerlund, CEO, Xintela AB
- 16:35 – 16:50 Mapping the adaptive immune response to SARS-CoV2
Stephan Thorgrimsen, CEO, Immunitrack
- 16:50 – 17:00 Summary and conclusions
Søren Bregenholt, Chairman of the board, Medicon Valley Alliance, CEO, Macrophage Pharma
- 17:10 – 18:00 Networking & tapas**

Speakers

In order of appearance



PETTER HARTMAN

CEO | Medicon Valley Alliance

Petter Hartman is the CEO of Medicon Valley Alliance since June 2015. Petter has a background in the European Regional Development Fund (ERDF) where he worked to support cross-border collaborations at a Nordic level. At Medicon Valley Alliance, Petter is responsible for the development of future strategies for the Medicon Valley region, project development, funding strategies and key stakeholder management. Petter also serves as member of several advisory boards at a regional and European level.



CHRISTIAN KETELS

Global expert on economic competitiveness and clusters Visiting Executive | Harvard Business School

Christian Ketels is a global expert on economic competitiveness and clusters. He currently is a Visiting Executive at Harvard Business School, and Co-Chair of the Board of Directors of Innovation Fund Denmark. Christian chairs the advisory board of TCI, a global network in cluster-based economic development. He served as Chief Economist of the Boston Consulting Group in 2018-2019, where he was heading the Center for Macroeconomics at the BCG Henderson Institute.



ENRIQUE ÁLVAREZ FERNÁNDEZ

Managing Director and General Manager | Merck Group

Enrique Álvarez Fernández has been leading organizations in five different countries for over 15 years and is used to working in other cultures (USA, UK, Sweden, Denmark) in contexts of high complexity, transformation and competitiveness, providing vision and strategic guidance. Previous experience includes more than 10 years in strategic consulting and a solid academic background with a bachelor's in chemistry and an MBA from IE Business School.



BERKELEY VINCENT

**Managing Director Nordic Cluster |
Janssen Europe, Middle East & Africa**

Berkeley Vincent took on the role of new Managing Director for the Nordic markets from July 1, 2019. Berkeley Vincent has a track record in strategic leadership at global, regional and country level within Janssen, most recently as VP for Customer and Digital Strategy, which places him at the forefront of the increasingly important topics of advanced analytics and digital transformation for the pharmaceutical business. Berkeley has worked in global and regional strategic roles in both the US and Europe. He has a BSc in Management from Dublin Institute of Technology and an MBA from DePaul University, Chicago.



ANNE-MARIE LEVY RASMUSSEN

CEO | Innovation Fund Denmark

Anne-Marie Levy Rasmussen joined the Innovation Fund Denmark as CEO in February 2020. She has long experience within research and innovation from working both at universities and in international industry, and has insights into political processes. Anne-Marie Levy Rasmussen has since 2007 held management positions at GSK in Denmark, London and most recently at the company's headquarters for vaccines in Belgium. She was the vice president of the Danish Academy of Technical Sciences and has held board positions at The Danish National Advanced Technology Foundation and the European Physical Society.



DARJA ISAKSSON

Director General | Vinnova

Darja Isaksson is the Director General at Vinnova – Sweden's Innovation Agency. She is a member of the Swedish Government's Digital Advisory Council and was previously a member of the Swedish Government Innovation Council. Darja has been selected as one of Sweden's 15 leading super-talents (by Resumé magazine in 2013) and one of the country's 12 most powerful opinion shapers and agent for social change. Darja Isaksson is also the founder of two successful digital agencies.



AMANDA HAYWARD

Partner | Eir Ventures

Amanda Hayward is a molecular biologist and has spent 18 years on the business side with a focus on company building, venture investment, executive leadership, finance and business development.

Amanda has been a co-founder of and operator within several academic and pharma-sourced spin-outs, and she has held interim executive management roles in a number of these spinouts. Amanda's venture experience comes from being a partner-level member of two US based venture funds, with an international investment scope. Amanda has board level and operational experience in the US and Europe, including the Nordics.



MARTINA KVIST REIMER

Executive Vice President | Red Glead Discovery

Martina Kvist Reimer has more than 20 years' experience from pharma and biotech in various leading project and management roles. She is the Executive VP and co-founder (2011) of Red

Glead Discovery, a CRO focused on delivering services for integrated drug discovery and which is one of the fastest growing life science companies in Sweden. At Red Glead Discovery, Martina holds responsibility for the management of the company's internal project portfolio and strategic collaborations with academic researchers.



MORTEN AGERTOUG NIELSEN

Associate Professor | CMP, Dept. of Immunology and Microbiology, University of Copenhagen

Morten Agertoug Nielsen is Associate Professor at the Department of Immunology and Microbiology at University of Copenhagen. Together with Associate Professor Adam Sander and Professor Ali Salanti, Morten has founded the spinout company NextGen Vaccines, which along with the private biotech company ExpreS2ion has created the joint venture company AdaptVac. In March, the consortium received a 2.7 million euro grant from the EU research program Horizon for their work to develop a vaccine against COVID-19. The researchers have also received support from the Carlsberg Foundation for their vaccine related work.



EVY LUNDGREN-ÅKERLUND

CEO | Xintela AB

Evy Lundgren-Åkerlund has been the CEO of Xintela since 2009. Evy is a doctor of medical science and a senior lecturer. She was the founder of Xintela and has extensive experience in biomedical research and development. Evy has previously held senior positions in both academia and industry. She was the founder of Cartela AB, where she was the CEO and Head of Research from 2000-2007. Further, Evy was Director of Operations/CEO of Ideon Bioincubator/Lund Life Science Incubator from 2008-2012.



STEPHAN THORGRIMSEN

CEO | Immunitrack

Stephan Thorgrimsen is one of Immunitrack's two co-founders. He holds a PhD in biochemistry from the University of Copenhagen, Denmark and he authored or co-authored numerous peer-reviewed articles during his research career. In 2013, Stephan completed an MBA from the prestigious Copenhagen Business School and cofounded Immunitrack where he is currently the CEO.

MODERATOR



SØREN BREGENHOLT

**Chairman of the board | Medicon Valley Alliance
CEO | Macrophage Pharma**

Søren Bregenholt serves as Chief Executive Officer in UK-based Macrophage Pharma. Since 2002, Søren has held a number of management positions in Danish pharma and biotech, including Corporate Vice President, Head of External Innovation & Strategy in Novo Nordisk, Chief Operating Officer in Symphogen and latest as Chief Business Officer in IO Biotech. Søren has acted as advisor to the Dean of the Medical and Science faculties at his alma mater. He has served as Chairman of Medicon Valley Alliance since 2014.

MODERATOR



SARAH LIDÉ

**Senior Strategy and Project Manager |
Medicon Valley Alliance**

Sarah Lidé is a Senior Strategy and Project Manager with Medicon Valley Alliance, where she serves the network with strategic and market insights through trend briefings, while managing projects on behalf of the network organisation. Before her current role, she was a strategic consultant with PwC for close to a decade, where she has led a variety of multi-stakeholder projects related to life science. Her work requires her to keep abreast of the latest trends and developments in a broad range of industries. She has also written a number of articles and thought leadership publications which have been published in commercial magazines.

The Networks

Apart from the different life science-related standalone events such as Boost Seminars and Good Morning meetings, Medicon Valley Alliance also facilitates bi-national networks initiated and driven by our members and the secretariat collectively. To participate in the Medicon Valley Alliance networks your organization has to be a member of Medicon Valley Alliance. Once you have paid the member fee, joining the networks involves no additional costs.



Medicon Valley Alliance Executive Club is an exclusive network of executives from Medicon Valley Alliance's member companies and organizations. The main objective with the Medicon Valley Alliance Executive Club is to provide a relevant and informal setting for networking among Medicon Valley executives.



Medicon Valley Alliance R&D Network focuses on best practice and current challenges for industry-academia collaboration and the commercialization of R&D in the Medicon Valley region. Here we address how to strengthen collaboration and knowledge sharing to stimulate start-up, scale-up, commercialization and growth.



MICROBIOME NETWORK

Medicon Valley Alliance

Our ambition with the Medicon Valley Alliance Microbiome Network is to help raise the bar and increase opportunities for researchers from industry, academia and the hospital sector to meet and promote an area where the region has a high international competitive edge. The network is a stepping stone to the future of microbiome R&D in Medicon Valley.


ONCOLOGY NETWORK

Medicon Valley Alliance



Medicon Valley Alliance Oncology Network is a network initiated by Danish and Swedish business and academia within the field of oncology. The ambition is to provide a forum for the exchange of knowledge about oncology R&D in general and the challenges facing entrepreneurs within the fields of oncology in particular.

Medicon Valley Alliance




MEDTECH NETWORK

Given the high number of innovative medtech companies in the Öresund region, it is time we make use of our collected knowledge to increase growth in this sector. Medicon Valley Medtech Network gathers the region's medtech industry to create new partnerships and business opportunities.

The Projects

Increased cross-border collaboration between hospitals, universities and the industry is key to create a strong innovation community and will ensure a more efficient use of our common resources as well as strengthening Medicon Valley's competitiveness. MVA has a strong track record when it comes to project development and securing external funding. MVA facilitates and participates actively in various project constellations and working groups to strengthen Swedish and Danish life science.



Greater Copenhagen life science analysis

The primary objective of the project, developed and managed jointly by the Medicon Valley Alliance and Øresundsinstituttet, is to analyze the need for competencies and skills in the regional life science industry in Medicon Valley and to support the development of the integrated labor market in Greater Copenhagen. The three-year project is co-financed by Interreg ØKS and started in January 2019.

Hanseatic League of Science



Interconnection infrastructures
for life science research and innovation

HALOS

Hanseatic League of Science (HALOS) will build a unique collaboration between Hamburg and South-West Scandinavia, that brings together the four unique research facilities MAX IV, ESS, DESY and European XFEL. The aim is to match Life Science research questions with expertise on how to apply electrons, neutrons, and synchrotron and FEL-light. The three-year project is financed by Interreg ØKS and started 1st of February 2019.



ReproUnion



Across borders in Reproductive Medicine

ReproUnion

ReproUnion is a cross-border collaboration between Sweden and Denmark within the area of reproductive medicine, funded by EU Interreg ØKS, Region Skåne, Region Hovedstaden and Ferring Pharmaceuticals. In 2020 we celebrate the 10-year anniversary of the Repro Collaboration, where the regional universities, hospitals and industry partners are working together to address five major global reproductive challenges, which are of great individual and social concern.

Microbiome Signature Project

GREATER
COPENHAGEN

Greater Copenhagen as a global centre for microbiome research

MICROBIOME
SIGNATURE PROJECT

Microbiome Signature Project

Started in August 2019, the project is a three-year Inter-reg-financed collaboration for investment promotion and talent attraction, and is jointly led by Medicon Valley Alliance, Copenhagen Capacity and Invest in Skåne. The aim is to position Medicon Valley and Greater Copenhagen as a global centre for microbiome research by actively identifying and attracting international research facilities and life science talents to the region.

DiaUnion

Medicon Valley Center for diabetes,
autoimmunity and prevention



DiaUnion

Over a long period of time, the region has built up strong and internationally recognised competences within the fields of screening, genetics and immunology in type 1 diabetes and related autoimmune diseases. From January 2020 to June 2022, MVA, Steno Diabetes Center and Lund University will research novel biomarkers for type 1 diabetes and, in parallel, develop the next step in a platform to become a center of excellence for research in type 1 diabetes and related autoimmune diseases.

Medicon Valley Alliance
Arne Jacobsens Allé 15
2300 Copenhagen S
www.mva.org



A special thanks to our sponsors:

H Ø I B E R G
European Patent Attorneys

**NORDIC
CHOICE
HOTELS**



medicon valley alliance

Creating Opportunities